hCTMO1-calicheamicin

immunoconjugate of the monoclonal antibody hCTM01 directed against polymorphic epithelial mucin covalently bound to calicheamicin by an amide linker; for treatment of epithelial ovarian cancer; structure in first source

Also Known As:

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Beyer, Carl F: 1 article (03/2005)
2.	Hamann, Philip R: 1 article (03/2005)
3.	Hinman, Lois M: 1 article (03/2005)
4.	Lindh, Delores: 1 article (03/2005)
5.	Mountain, Andrew: 1 article (03/2005)
6.	Shochat, Dan: 1 article (03/2005)
7.	Upeslacis, Janis: 1 article (03/2005)
8.	Berger, Mark S: 1 article (04/2003)
9.	Chan, Stephen Y: 1 article (04/2003)
10.	Coleman, Robert E: 1 article (04/2003)

Related Diseases

1.	Ovarian Epithelial Carcinoma 06/01/2000 - "We have performed a phase I study of the cytotoxic immunoconjugate CMB-401 in women with epithelial ovarian cancer (EOC). " 06/01/2000 - "Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer." 04/01/2003 - "We evaluated CMB-401 as monotherapy for the treatment of recurrent platinum-sensitive epithelial ovarian carcinoma (EOC). " 04/01/2003 - "A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma."
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/01/2003 - "gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia], we hypothesize that the amide linker used in CMB-401 may have contributed to its failure to induce PR in patients in this study. "
3.	Neoplasms (Cancer) 03/01/2005 - "The hCTM01-NAc-gamma calicheamicin DM amide conjugate, referred to as CMB-401, shows targeted killing of MUC1-expressing cells in vitro and produces pronounced dose-related antitumor effects over an 8-fold dose range against a MUC1-expressing, ovarian xenograft tumor, OvCar-3. "
4.	Breast Neoplasms (Breast Cancer) 03/01/2005 - "The specificity of CMB-401 was confirmed by comparing its antitumor effects with those of an isotype-matched nonspecific conjugate against the MX-1 breast carcinoma. "

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)
2.	Amides
3.	Platinum
4.	Gemtuzumab (Mylotarg)
5.	Calicheamicins